Mutation profiling of pleomorphic xanthoastrocytoma and giant cell glioblastoma arising in a PXA reveals BRAF V600E mutations.

<p>The sections on the left illustrate SNaPshot genotyping and the sections on the right depict Sanger sequencing of <i>BRAF</i> exon 15 for the same samples. The top panel shows genotyping data obtained with normal male genomic DNA (Promega, Madison, WI). The lower panels illustrate BRAF V600E (c.1799T>A) mutation detection (arrows) in tumor DNA derived from formalin-fixed paraffin-embedded specimens of representative examples of: PXA (BT21), anaplastic PXA (BT22) and gcGBM arising in a PXA (BT49). Assays: (1) <i>EGFR</i> 2235_49del R; (2) <i>NRAS</i> 38; (3) <i>BRAF</i> 1799; (4) <i>NRAS</i> 182; (5) <i>PIK3CA</i> 263; (6) <i>TP53</i> 742; (7) <i>CTNNB1</i> 95 and (8) <i>CTNNB1</i> 122.</p

Clinical Data and Summary of Results.

<p>PXA – pleomorphic xanthoastrocytoma; PXA (m) – pleomorphic xanthoastrocytoma with mesenchymal-like growth pattern; aPXA – anaplastic pleomorphic xanthoastrocytoma; NA – Not assessed.</p

ONC201-mediated CSC- and Wnt-pathway-related changes in gene expression.

<p>ONC201-mediated CSC- and Wnt-pathway-related changes in gene expression.</p

ONC201-mediated stem cell-related changes in gene expression.

<p>ONC201-mediated stem cell-related changes in gene expression.</p

CSC-related gene expression in solid tumors as a potential biomarker of response for ONC201.

<p>Distribution of ONC201 efficacy (IC50) in >1000 GDSC cell lines based on basal RNA expression of (A) <i>TCF3</i>, (B) <i>HES7</i>. (C) Distribution of ONC201 efficacy (IC50) in >1000 GDSC cell lines based on fulfillment of at least two expression based criteria (low expression of <i>ID1/CD44</i> and high expression of <i>TCF3/HES7</i>) against cell lines that fulfilled none. P value and D statistic are indicated.</p